The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.
The global bi-specific MAbs market was valued at about $1.56 billion in 2019 and is expected to grow to $2.93 billion in 2020 at a compound annual growth rate (CAGR) of 87.6%. The COVID-19 restrictions caused a slowdown in growth from 2018 due to missed patient visits affecting potential new patients who deferred the care, whereas existing patients remained on their treatment. However, with the sales beginning to recover slowly, the market is expected to stabilize and reach $6.12 billion by 2023 at a CAGR of 27.8%.
